The journal NEJM Evidence publishes an Editorial regarding the results of the clinical trial with MV140 in recurrent urinary tract infections recently published in that journal.
The editorial commentary by Dr. Bold (Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis) highlights that recurrent UTIs are currently addressed with a wide range of clinical practices often based on experience rather than high-quality evidence.
The commentary emphasizes the novelty of the therapeutic approach with MV140 and the clinical importance of the results based on the strict definition of the cases included. Considers it important to understand the mechanisms of action involved, which could depend, among others, on a selective action on colonization by bacterial species included in the MV140 formulation and/or generation of cross-protection against other bacterial species.